Table 1. Patient characteristics.
| Characteristics | N = 29 | % |
|---|---|---|
| Initial diagnosis | ||
| Age | 57, 1 (37, 2–74, 1) | |
| Gender (M / W) | 18M / 11W | 62% / 38% |
| KPS (median) | 80 | |
| 60 | 1 | 4% |
| 70 | 11 | 38% |
| 80 | 14 | 48% |
| 90–100 | 3 | 10% |
| MMS | ||
| Normal | 22 | 85% |
| Abnormal | 4 | 15% |
| Steroids | 20 | 71% |
| RPA classification | ||
| III | 4 | 15% |
| IV | 19 | 73% |
| V–VI | 3 | 12% |
| Type of surgery | ||
| Gross total resection | 28 | 96% |
| Other | 1 | 4% |
| MGMT status | ||
| Methylated / Unmethylated | 6 / 21 | 22% / 78% |
| IDH 1/2 mutation | 0 | 0% |
| First line treatment | ||
| Radiotherapy and temozolomide | 27 | 93% |
| Radiotherapy and BCNU | 2 | 7% |
| Recurrence | ||
| Age | 58 (38, 2–75, 7) | |
| KPS (median) | 70 | |
| 60 | 6 | 21% |
| 70 | 15 | 52% |
| 80 | 7 | 24% |
| 90 | 1 | 3% |
| Steroids | 24 | 86% |
| Treatment at progression | ||
| Gliadel | 29 | 100% |
| Bevacizumab | 14 | 48% |
| Total number of lines | ||
| 2 | 6 | 21% |
| 3 | 14 | 48% |
| 4 or 5 | 9 | 31% |
KPS: Karnofsky Performans Satus; MMS: MiniMental Status; RPA: Recursive Partitioning Analysis